|
NCCN Tumor Boards: Optimizing Treatment of Chronic Phase Chronic Myeloid Leukemia |
1.00 |
11/25/2025 - 12:00am to 05/17/2026 - 12:00am |
|
Optimizing Patient Care Coordination Between Academic and Community Settings |
1.00 |
12/01/2025 - 12:00am to 11/30/2026 - 11:59pm |
|
Deploying Novel Therapies for Acute Lymphoblastic Leukemia |
1.00 |
12/01/2025 - 12:00am to 11/30/2026 - 11:59pm |
|
Role of Allogeneic Transplants in Acute Lymphoblastic Leukemia |
0.50 |
12/01/2025 - 12:00am to 11/30/2026 - 11:59pm |
|
Integrating New Therapies for the Treatment of Chronic Phase Chronic Myeloid Leukemia |
0.50 |
12/01/2025 - 12:00am to 11/30/2026 - 11:59pm |
|
Incorporating TKIs in the Treatment of Myelofibrosis |
0.50 |
12/01/2025 - 12:00am to 11/30/2026 - 11:59pm |
|
Emerging Treatment Strategies for High-Risk Myelodysplastic Syndromes |
0.50 |
12/01/2025 - 12:00am to 11/30/2026 - 11:59pm |
|
Evolving Treatment Strategies for Acute Myeloid Leukemia |
1.00 |
12/01/2025 - 12:00am to 11/30/2026 - 11:59pm |
|
Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma |
1.50 |
12/01/2025 - 12:00am to 11/30/2026 - 11:59pm |
|
Monitoring Toxicities in the Ambulatory Setting |
1.00 |
12/01/2025 - 12:00am to 11/30/2026 - 11:59pm |
|
The Role of Minimal Residual Disease in Hematologic Malignancies |
1.00 |
12/01/2025 - 12:00am to 11/30/2026 - 11:59pm |
|
Comprehensive Care for Adult Survivors of Hematologic Malignancies |
0.50 |
12/01/2025 - 12:00am to 11/30/2026 - 11:59pm |
|
Emerging Treatment Options for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
0.75 |
12/01/2025 - 12:00am to 11/30/2026 - 11:59pm |
|
Evolving Treatment Options for Relapsed/Refractory Follicular Lymphoma |
0.75 |
12/01/2025 - 12:00am to 11/30/2026 - 11:59pm |
|
Optimizing First-Line Therapy for Diffuse Large B-Cell Lymphoma |
0.75 |
12/01/2025 - 12:00am to 11/30/2026 - 11:59pm |
Facebook
X
LinkedIn
Forward